alexa Role of Liver in Glucose Metabolism | OMICS International
ISSN: 2165-7548
Emergency Medicine: Open Access
Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Role of Liver in Glucose Metabolism

Aparajita Dey*

Life Science Division, AU-KBC Research Centre, MIT Campus of Anna University, Chromepet, Chennai-600044, India

*Corresponding Author:
Aparajita Dey
Life Science Division
AU-KBC Research Centre
MIT Campus of Anna University
Chromepet, Chennai-600044, India
E-mail: [email protected]

Received Date: September 12, 2013; Accepted Date: September 13, 2013; Published Date: September 17, 2013

Citation: Dey A (2013) Role of Liver in Glucose Metabolism. Emergency Med 3:e133. doi:10.4172/2165-7548.1000e133

Copyright: © 2013 Dey A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Emergency Medicine: Open Access

Introduction

Liver is the primary organ for glucose metabolism. Apart from expressing the enzymes involved in glucose metabolism and regulation, liver possesses numerous enzymes involved in detoxification and toxicity enhancement (Phase I and Phase II). Also, most substances, upon entry into the body are primarily subjected to metabolism in the liver. Reports dealing with the effects of high glucose on liver are discussed in the following sections of this mini-review.

Liver Damage in Diabetes

Several studies have shown that significant oxidative stress and liver damage occurs in diabetes. A study using Non- Obese Diabetic (NOD) mice showed elevated serum enzymes associated with liver damage and apoptosis as indicated by marked DNA fragmentation and all these changes were decreased with selenium treatment [1]. Another study indicated that Streptozotocin (STZ)-induced diabetic rats (animal model for Type I diabetes) exhibited increased lipid peroxidation and decreased levels of antioxidant enzymes- catalase, glutathione peroxidase and Superoxide Dismutase (SOD) in liver which were reversed with aucubin [2]. The protein expression of the antioxidant enzymes, SOD and catalase which are involved in the detoxification of Reactive Oxygen Species (ROS) were found to be decreased in the STZ-induced diabetic rat liver tissues and vitamin C or lipoic acid treatments elevated their levels [3]. STZ mediated hyperglycemia decreased glutathione peroxidase, catalase, glucose-6- phosphate dehydrogenase and transketolase activities in liver tissue of diabetic rats and although treatment with melatonin slightly elevated the levels of the antioxidant enzymes, it markedly reversed the activities of glucose-6-phosphate dehydrogenase and transketolase [4].

Another study reported that glucose levels as indicated by glucose oxidase, glycated haemoglobin, an indicator of glycative stress, and the 8-oxo-2’- deoxyguanosine (8-oxodG) content of DNA, an indicator of oxidative DNA damage, in the liver of STZ-diabetic rats were much higher compared with control rats [5]. Similar observations were reported in another study showing that the nuclear and mitochondrial DNA levels of 8-hydroxy-2’-deoxyguanosine (8-OHdG), another biomarker for oxidative DNA damage increased several fold in STZ treated rats and these changes were reversed with rice bran oil treatment [6]. Liver 8-OHdG levels in STZ treated rats were significantly decreased by combined treatment with insulin and antioxidant (probucol or vitamin E), but not by insulin treatment alone [7].

STZ induced diabetes led to the increased expression of liver and hepatocyte inducible Nitric Oxide Synthase (iNOS) [8]. The activation of Peroxisome Proliferator Activated Receptor alpha (PPAR alpha) was shown to protect STZ treated mice against the toxicity of acetaminophen, a potent hepatotoxicant [9]. Another study observed disparate effects of alpha lipoic acid on the decreased liver SOD and Glutathione (GSH) levels and increased lipid peroxidation in STZ treated rats [10]. The livers of STZ treated rats showed increased oxidation of GSH, lipoperoxides and activity of xanthine oxidase, a superoxide-generating enzyme [11]. Impaired proteosome activity needed to degrade oxidized proteins was observed in the cytosol of STZ treated rats [12]. Livers from STZ treated rats have been shown to exhibit increased levels of gamma-glutamyltranspeptidase, a premalignant marker [13].

Liver mitochondria from STZ-diabetic rats exhibited less susceptibility to oxidative damage (induced by Fe3+/Adenosine 5’-diphosphate (ADP) xanthine/xanthine oxidase), compared to normal rats [14]. Increase in apoB-48 lipoproteins was observed, due to significantly less sulfate incorporation into heparan sulfate proteoglycans in livers of STZ-treated rats [15]. Fatty Aldehyde Dehydrogenase (FALDH), a key component of the detoxification pathway of aldehydes arising from lipid peroxidation events was decreased in two models of insulin-resistant mice: db/db and high fat diet mice and STZ-treated rats, suggesting that FALDH dysregulation occurs both in hyperinsulinemic insulin-resistant state and hypoinsulinemic type 1 diabetes models [16].

Non-alcoholic fatty liver disease, a spectrum of liver damage that ranges from relatively benign hepatic steatosis to potentially fatal cirrhosis is very closely associated with Type 2 diabetes. The clearance of 4-hydroxynonenal, a major product of lipid peroxidation, by the enzymes Glutathione-S-Transferase (GST), Aldehyde Dehydrogenase (ALDH), and Alcohol Dehydrogenase (ADH) was impaired in liver microsomes and mitochondria of BB/WOR diabetic rats [17]. An elevation of both alpha- tocopherol and Coenzyme Q contentantioxidant enzymes, which may be involved in the elimination of mitochondrially generated ROS and decreased susceptibility of liver mitochondria to oxidative damage, was observed in Goto-Kakizaki (12-month-old diabetic) rats, a model of non-insulin dependent diabetes mellitus than in the mitochondria from normal rats [18]. Further, the mRNA expression of Heme Oxygenase-1 (HO-1), an important sensitive marker of the stress response was found to be increased in spontaneously diabetic rats [19]. Lipoperoxidative aldehydes were shown to accumulate in liver microsomes and mitochondria at a higher rate in spontaneously diabetic BB/WOR rats than in control non-diabetic animals [20].

The Cytochrome P450 (CYP) enzymes which play a significant role in hepatotoxicity - CYP2A6, 2E1, and 3A4/5 were found to be increased in hepatocytes of patients with fatty liver due to obesity or diabetes [21]. Due to the limited availability of liver samples from humans and the tedious process of liver biopsy, the study of effect of high glucose in human liver has been restricted to very few reports.

Studies have also stressed upon the use of herbal preparations in protecting against liver damage in diabetes. A new thiazolidinedione analog was found to be effective in alleviating oxidative stress in alloxan treated rats [22]. Another study observed that tetrahydrocurcumin, one of the active metabolites of curcumin lowered oxidative stress in livers of STZ- nicotinamide induced diabetic rats [23]. An aqueous extract of Albizzia lebbeck was effective in decreasing oxidative stress in alloxan treated rats [24]. A bark extract of Helicteres isora exhibited hypoglycemic and hepatoprotective activity in STZ induced diabetic rats [25]. The antioxidant effect of an aqueous extract of Scoparia dulcis, was observed in rats with STZ-induced diabetes [26]. Similarly, a few more studies have explored the hepatoprotective effects of Indian medicinal plants in diabetes [27-30].

Use of Hepatocytes to Investigate the Effects of High Glucose

In vitro studies using hepatocytes and HepG2 cells have provided valuable insights into the mechanisms of glucose toxicity in liver. Glycolytic enzymes- glucokinase and phosphofructokinase-2/ fructose bisphosphatase-2 were found to play coordinate roles in the elevated hepatic glycolysis observed in hepatocytes obtained from in insulin-resistant Zucker fa/fa rats [31]. Human hepatocyte cell lines, Huh7 treated with high glucose alone or in combination with proinflammatory cytokines, were found to exhibit increased levels of the transcription factor Nuclear Factor kappa-B (NF-kappaB) and enhanced coagulation-related gene expression and the effects were mediated, at least partly, by the generation of oxidative stress [32]. Hepatocytes from Zucker fa/fa rats were found to show increased sensitivity of glycogen synthesis to phosphorylase-a and impaired expression of the glycogen-targeting protein R6 [33]. Carbohydrate response element binding protein was found to directly promote lipogenic enzyme gene transcription in hepatocytes isolated from wild type mice and exposed to high concentration of glucose [34]. A study using mouse Hepatocytes (HEP6-16) reported that decreased ATP content downregulated mitochondrial uncoupling Protein 2 (UCP2) expressions, thus affecting the energy metabolism [35].

However, the use of hepatocytes for a long period proves to be difficult due to the unstable expression of differentiated functions, low cell survival and rapid cell senescence.

Use of Hepatoma Cell Lines, Hepg2 to Investigate the Effects of High Glucose

The human hepatoma cell lines, HepG2 have been used extensively to study hyperglycemia in vitro. The expression of hepatic Scavenger Receptor class B type I (SR-B1) which binds High Density Lipoprotein (HDL) particles that mediate reverse cholesterol transport and thus lowers the risk of atherosclerosis was observed to be suppressed in HepG2 cells exposed to high glucose [36]. In primary rat Hepatocytes and in HepG2 cells, the transcription of the human apolipoprotein (apo) A-II gene was upregulated by glucose [37]. High glucose up regulated the transcription of human Phospholipids transfer protein which plays an important role in human plasma HDL metabolism and increased mRNA levels for several genes that are functionally important in HDL metabolism, including human ATP-binding cassette transporter A1, Apo A-1, SR- B1, and hepatic lipase in HepG2 cells [38]. High glucose led to the decrease of mitochondrial DNA content and inhibition of mitochondrial function in HepG2 cells [39]. The effects of a high concentration of glucose on the insulin receptor-down signaling were investigated in HepG2 cells to delineate the molecular mechanism of insulin resistance under glucose toxicity and high concentration of glucose caused phosphorylation of IRS-1, leading to selective attenuation of metabolic signaling of insulin [40]. Further, the phosphorylation of IRS-1 with high glucose treatment was blocked only by Protein Kinase C (PKC) inhibitors. The surface binding of asialo- orosomucoid, a well-documented ligand for hepatic receptor for asialoglycoproteins, increased significantly with increasing glucose concentrations in HepG2 cells [41].

Thus, as evidenced through the above studies utilizing in vivo animal models and invitro models of hepatocytes and HepG2 cells, metabolism of high concentrations of glucose in liver may impair several cellular processes thus leading to injury.

References

Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Relevant Topics

Recommended Conferences

Article Usage

  • Total views: 14378
  • [From(publication date):
    October-2013 - Jul 18, 2018]
  • Breakdown by view type
  • HTML page views : 10523
  • PDF downloads : 3855
 

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7